The initial use of combination antimicrobial therapy for gram-negative infections is usually ... risk of superinfection with more-resistant bacteria or fungi. There are no clinical data that ...

Nevertheless, we would recommend it only in cases of severe infection by MDR gram-negative bacteria as a second-line drug at appropriate dosages and with monitoring of renal function and ...

Basilea Pharma awarded USD 7.3 million additional CARB-X funding to develop new drug candidate from a novel class of antibiotics: Allschwil, Switzerland Thursday, December 26, 202 ...

Veterans Affairs clinics, quarterly antibiotic use reports and adverse event letters were linked to lower antibiotic ...